Aardvark Therapeutics, Inc. income statement

In fiscal 2025, Aardvark Therapeutics, Inc. reported revenue of $0 and net income of −$57.6m, or −$2.93 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Aardvark Therapeutics, Inc.: income statement, annual
Fiscal year	2025Dec 2025	LTMJun 2026
Revenue	0	0
Research and development	49	55
General and administrative	14	19
Operating income	−63	−74
Income tax	0	—
Net income	−58	−70
Diluted EPS	−$2.93	−$3.20
Diluted shares (average)	20m	22m
EBITDA	−63	−74

US$ millions unless shown otherwise. Fiscal quarters.

Aardvark Therapeutics, Inc.: income statement, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	0	0	0	0	0
Research and development	8	13	14	14	17	10
General and administrative	3	3	4	4	6	5
Operating income	−10	−16	−18	−19	−22	−15
Net income	−9	−14	−16	−18	−22	−14
Diluted EPS	−$0.71	−$0.66	−$0.75	−$0.81	−$0.99	−$0.66
EBITDA	−10	−16	−18	−19	−22	−15

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aardvark Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aardvark Therapeutics, Inc.